潤陽科技(300920.SZ):擬與傅利葉簽訂投資意向協議
格隆匯5月26日丨潤陽科技(300920.SZ)公佈,為滿足公司戰略發展需要,拓展公司業務領域,在保持公司自有主營業務穩健發展的同時,豐富公司產業佈局,提升公司綜合競爭力,公司擬與傅利葉簽訂《投資意向協議》,擬通過認繳標的公司新增註冊資本額的方式進行投資,傅利葉的投前整體估值為人民幣80億元,公司擬以現金方式合計投資不超過人民幣3億元。
公司擬對上海傅利葉智能科技有限公司(以下簡稱“傅利葉”或“標的公司”)進行增資並獲得其股權,本次擬簽訂的《投資意向協議》僅就意向交易方案進行初步確定,具體的交易方案尚需根據審計、盡職調查等結果由雙方協商確定,以簽署的正式協議為準。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.